Drug intelligence / Profile preview

BR012

Development stage: Preclinical
Lead developer: Brise Pharmaceuticals

Overview

BR012 is an investigational drug candidate currently in the discovery phase, developed by Brise Pharmaceuticals for the prevention of migraine. While the company's lead program, BR005, is a small molecule targeting the calcitonin gene-related peptide (CGRP) pathway, the specific biological target and modality for BR012 remain undisclosed. The program is part of a broader portfolio aimed at addressing unmet needs in headache and pain management.

Beyond the preview

Go deeper on BR012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR012.

Explore the full profile